BS_BA6AZWB3
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 1.56
- os_event
- false
- age_years
- 36.529
- sex
- M
- race
- White
- new_clusters
- S1
- umap1_2d
- -2.062505999
- umap2_2d
- -10.51515108
- umap1_3d
- -2.262364248
- umap2_3d
- -0.888609609
- umap3_3d
- 6.632171115
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.460
- NOTCH_SIGNALING+0.440
- COAGULATION+0.420
- INFLAMMATORY_RESPONSE+0.410
- APICAL_SURFACE+0.380
- BILE_ACID_METABOLISM+0.370
- IL6_JAK_STAT3_SIGNALING+0.370
- ALLOGRAFT_REJECTION+0.340
- KRAS_SIGNALING_UP+0.340
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V1-0.640
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V2-0.570
- DNA_REPAIR-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.390
- MITOTIC_SPINDLE-0.370
- OXIDATIVE_PHOSPHORYLATION-0.360
- MTORC1_SIGNALING-0.290
- PI3K_AKT_MTOR_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3XY76V8T | Ganglioglioma | — | 0.932 |
| 2 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.926 |
| 3 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.925 |
| 4 | MDT-AP-1152 | Med | Medulloblastoma | 0.924 |
| 5 | TCGA-75-6203-01A-11R-1755-07 | — | cohortA1 | 0.923 |
| 6 | MDT-AP-3282 | Med | Medulloblastoma | 0.923 |
| 7 | SRR1444622 | GTEX | — | 0.922 |
| 8 | SRR1472150 | GTEX | — | 0.919 |
| 9 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.917 |
| 10 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |